Abstract: A multibranch implantable device including a main body including a tubular element having wall defining a main lumen, the tubular element having a first end defining a first opening into the main lumen and a second end defining a second opening in the main lumen, the tubular element including at least one side branch portal defining an aperture through the wall between the first longitudinal end and the second longitudinal end of the tubular element and at least one secondary body defining a secondary lumen, the at least one secondary body operable to be deployed with a portion of the secondary body positioned in the at least one side branch portal of the main body.

Abstract: In one aspect, compounds and compositions that modulate a bromodomain and methods of making and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with inhibition of a bromodomain such as, for example, cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: In one aspect, compounds and compositions that modulate a bromodomain and methods of making and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with inhibition of a bromodomain such as, for example, cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: In one aspect, compounds and compositions that modulate a bromodomain and methods of making and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with inhibition of a bromodomain such as, for example, cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5 and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.

Abstract: In one aspect, compounds and compositions that modulate a bromodomain and methods of making and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with inhibition of a bromodomain such as, for example, cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Provided herein are methods for antagonizing the action of an ?4-integrin to treat various pathophysiological conditions utilizing pharmaceutical compositions of compounds or pharmaceutically acceptable salts or stereoisomer(s) thereof of formula I where R1, R2, R3, R4, R5, X and R6 are as described herein.

Abstract: Provided herein are methods for antagonizing the action of an ?4-integrin to treat various pathophysiological conditions utilizing pharmaceutical compositions of compounds or pharmaceutically acceptable salts or stereoisomer(s) thereof of formula I where R1, R2, R3, R4, R5, X and R6 are as described herein.

Abstract: Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5, X and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomer(s) of these compounds. In addition methods are provided for antagonizing the action of an ?4-integrin to treat various pathophysiological conditions.

Abstract: Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5, X and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomer(s) of these compounds. In addition methods are provided for antagonizing the action of an ?4-integrin to treat various pathophysiological conditions.

Abstract: Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5 and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.

Abstract: Provided are compounds that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of CCR9 receptor activity.

Abstract: Provided are compounds that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of CCR9 receptor activity.